Spectrum Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Spectrum Pharmaceuticals
Public
Traded asNASDAQSPPI
S&P 600 Component
IndustryPharmaceuticals
HeadquartersHenderson, Nevada
Key people
Joseph Turgeon, Chief Executive Officer
Websitewww.spectrumpharm.com

Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California.

Drugs[edit]

Spectrum develops and markets drugs for treatments in oncology.

Approved drugs[edit]

  • Fusilev (Levoleucovorin) for injection is a drug that was approved by the U.S. Food and Drug Administration in 2008 for the US; the drug had been on the market in a number of European countries.
  • Folotyn (pralatrexate) is an antifolate drug marketed for relapsed or refractory peripheral T-cell lymphoma.
  • Zevalin (ibritumomab) is indicated for the treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including patients with rituximab-refractory follicular NHL. It is a CD-20 radio-antibody.[1]
  • Marqibo (Vincristine sulfate liposomes injection) is a sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo's approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. It was approved by the FDA in 2012.[2]
  • Beleodaq (belinostat) is an HDAC inhibitor for relapsed or refractory peripheral T-cell lymphoma.
  • Evomela (melphalan) is an alkalyating drug for multiple myeloma.[3]

In development[edit]

A number of drugs are currently investigated in clinical trials.[4]

  • Qapzola (apaziquone) is a synthetic bio-reductive prodrug intended for the treatment of non-invasive bladder cancer that is currently in Phase 3 studies. Allergan invested money in 2008 to help develop this medication further and bring it to the market.[5]
  • Rolontis (eflapegrastim) is in phase III trials for treatment of chemotherapy-induced neutropenia.[6]
  • Poziotinib is a quinazoline-based pan-HER inhibitor that blocks signaling through HER tyrosine-kinase receptors including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4). It is currently in phase II trials.

Spectrum terminated the development of Ozarelix, a luteinizing hormone releasing hormone antagonist for the treatment of benign prostatic hypertrophy in 2010.[7] Other previous drug candidates included ortataxel for the treatment of taxane-refractory tumors, and satraplatin for non-small cell lung cancer.

References[edit]

  1. ^ http://www.sppirx.com/310-spectrum-products-commercial.html
  2. ^ http://www.businesswire.com/news/home/20130903005631/en/Spectrum-Pharmaceuticals-Launches-Marqibo®-vinCRIStine-sulfate-LIPOSOME
  3. ^ http://www.sppirx.com/310-spectrum-products-commercial.html
  4. ^ Clinical trials
  5. ^ Marcial G (June 15, 2009). "Cancer drugs from Spectrum". Businessweek: 67.
  6. ^ https://clinicaltrials.gov/ct2/show/NCT02643420
  7. ^ http://www.businesswire.com/news/home/20100127005863/en/Spectrum-Pharmaceuticals-Terminates-Ozarelix-Development-Program-Benign

External links[edit]